Proposal of managerial standards for new product portfolio management in Brazilian pharmaceutical companies by Moreira, Raquel Assis & Cheng, Lin Chih
*Correspondence: R. A. Moreira. Núcleo de Tecnologia da Qualidade e da 
Inovação (NTQI), Departamento de Engenharia de Produção, Universidade 
Federal de Minas Gerais – UFMG. Av. Presidente Antônio Carlos, 6627 (Cam-
pus da Pampulha) - CEP 31270-901 - Belo Horizonte – MG, Brazil. E-mail: 
rmoreira@sjm.com
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 46, n. 1, jan./mar., 2010
Proposal of managerial standards for new product portfolio 
management in Brazilian pharmaceutical companies
Raquel Assis Moreira*, Lin Chih Cheng
Quality and Innovation Technology Center (NTQI), Production Engineering Department, Federal University of Minas Gerais
New Product Portfolio Management is aimed at helping decision-makers better select projects for new 
products based on key criteria for the manufacturer. The Brazilian pharmaceutical industry has been 
undergoing change due to stricter sanitary requirements following the enactment of the Generic Law in 
1999. This paper presents the results of a research study aimed at clarifying the rationale employed by 
national pharmaceutical companies in selecting and prioritizing their new product development projects. 
Consequently,  proposals for an analytical structure that could help these companies better select their 
products were produced. The research was carried out using case study methodology in which four 
different companies were investigated. The results of the field study confirmed that these companies 
had a non-structured Product Development System and that the selection of new product development 
projects was made on a non-systematic basis. The research also identified key criteria for the selection 
of projects of new pharmaceutical products, which provided the basis for the preparation of a proposal 
for a managerial standard for application of New Product Portfolio Management.
Uniterms: Portfolio management. Pharmaceutical products/development. Pharmaceutical industry. 
Brazil/pharmaceutical industry.
A gestão de portfólio de projetos de novos produtos visa a auxiliar os tomadores de decisão a selecionar 
projetos de novos produtos considerando critérios importantes para a organização. A indústria farmacêutica 
brasileira tem passado por transformações devido ao aumento das exigências sanitárias após a Lei de 
Genéricos, de 1999. O objetivo deste trabalho foi entender como as indústrias farmacêuticas brasileiras 
selecionam seus projetos de desenvolvimento de novos produtos e propor uma estrutura que possa 
auxiliar estas empresas a selecionar seus projetos de produtos. Foi utilizada a metodologia de estudo de 
caso e uma mostra de quatro organizações foi investigada. Os resultados indicam que essas empresas 
apresentam um desenvolvimento de produtos não estruturado e que a seleção de projetos de novos 
produtos é realizada de forma não-sistemática. Critérios importantes para a seleção de projetos de novos 
produtos foram identificados e utilizados para elaboração de um padrão gerencial para aplicação da 
gestão de portfólio de projetos de novos produtos.
Unitermos: Gestão de portfólio. Produtos farmacêuticos/desenvolvimento. Indústria farmacêutica. 
Brasil/indústria farmacêutica.
INTRODUCTION
The new product development process is intrinsi-
cally risky. Studies show that only approximately 60% 
of the products launched are subsequently considered 
commercially successful (Griffin, 1997). In the global 
pharmaceutical industry, the innovative medicine deve-
lopment process is even more challenging because of 
long development times, low success rates, high capital 
requirements for building a manufacturing facility, and 
great uncertainty in sales estimates (Blau et al., 2004). 
Brazilian pharmaceutical research consists basically 
of the development of formulations for administration of 
drugs whose patents have expired. The development of si-
milar and generic medicines is important for the country as 
it increases the competitiveness in the sector, thus favoring 
a price reduction and increasing the population’s access 
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to medicines. The generic medicines are interchangeable 
with patented medicines, presenting the same quality but 
at lower prices (Moreira, 2008). Generics can be defined 
as copies of drugs, based on the same active substance as 
the patented medicine, which are labeled with the active 
substance of the drug. Similar medicines are manufactu-
red as generic medicines but are labeled with their own 
brand-name.
The Brazilian pharmaceutical industry has un-
dergone changes to its management processes after the 
enactment of the Generic Law (Law 9787) in 1999. The 
stricter sanitary requirements have required an effective 
quality system and better strategic planning for new pro-
duct development. Consequently, the selection of new 
pharmaceutical product projects in the home industry 
requires a systematic process to support decision making. 
The new product portfolio management has the purpose 
of guiding this process. 
Cooper, Edgett and Kleinschmidt (1997) define 
portfolio management as a dynamic decision process, 
whereby a business’s list of active new product projects 
is constantly updated and revised. In this process, new 
projects are evaluated, selected and prioritized. Thus, 
portfolio management is a process for making decisions 
and allocating resources. Portfolio management has three 
main objectives: to develop projects strategically aligned 
with the business’s strategy; to maximize portfolio value; 
and to balance projects in terms of a number of parameters. 
This paper has the overall aim of ascertaining how the 
Brazilian pharmaceutical companies select their new pro-
duct development projects.  A structure is then proposed 
that can help these companies better select their products. 
Portfolio Management
Portfolio management – PM, is part of the strategic 
dimension of product development management. Re-
search on new product portfolio management presents 
a quantitative and qualitative dimension approach. The 
qualitative approach employs classifications, charts and 
diagrams such as scoring models and bubble diagrams. 
These approaches are described in the papers published 
by Bitman (2005), Mikkola (2001), Cooper, Edgett and 
Kleinschmidt (1998), and Roussel, Saad and Bohlin 
(1992). The quantitative approach employs mathemati-
cal methods in order to obtain data that support project 
selection. The quantitative approach is outlined in stu-
dies by Santiago and Vakili (2005), Blau et al. (2004), 
Loch and Kavadias (2001), Heidenberger and Stummer 
(1999). Some common points are shared in the discus-
sions among the authors of different research lines: the 
dynamism of the environment, and the interdependence of 
projects (Santiago, Vakili, 2005; Blau et al., 2004; Loch, 
Kavadias, 2001; Archer, Ghasemzadeh, 1999; Cooper, 
Edgett, Kleinschmidt, 1998).
Portfolio management models are frequently found 
in the literature and all share the objective of providing a 
methodology to guide the project selection process. The 
assessed portfolio management models and their main 
characteristics are presented in Figure 1. The identified 
characteristics in the Figure are as follows: i) focus of the 
model - the purpose for which the model was created; ii) 
sequence - the existence of defined steps for application of 
the model; iii) flexibility - the possibility of using different 
selection techniques; iv) time scale - the identification of 
either consecutive or simultaneous steps that guide the 
application of the model; v) continuous - a cyclic applica-
tion of the model; vi) systemic - the incorporation of the 
organizational levels (strategic, tactical and operational) 
comprising the organizational system; vii) important 
characteristics - any peculiar features of the model that 
should be mentioned.
The portfolio management models encompass the 
use of different techniques that should be chosen by the 
company, taking into consideration their ease-of-use, avai-
lable resources and time, and the team’s familiarity with 
the technique. The project selection techniques provide 
data or visual representations that allow the characteriza-
tion, comparison, evaluation and, consequently, selection 
of projects. Hall and Nauda (1990) and Heidenberger and 
Stummer (1999) classify the project selection techniques, 
which facilitates the choice of the most appropriate tech-
nique. 
Each portfolio management model presents specific 
characteristics, either to guide a certain economic activity 
or to refine a model previously described in the literature, 
or to take into consideration specificity by selecting pro-
jects with a high degree of interdependence, or selecting 
ongoing projects. Costello (1983) presented a bibliogra-
phic review of six project selection models developed in 
the 1960s and 1970s. There is a point in common among 
all the portfolio management models assessed: successful 
application depends on the choice of the project selection 
criteria. The literature presents some standard criteria 
(Oliveira, Rozenfeld, 2007; Bitman, 2005; Cooper, Edgett, 
Kleinschmidt, 1997), but each company needs to evaluate 
the importance of a given criterion to its business. 
Development of a portfolio management model 
for Brazilian pharmaceutical companies
Given the absence of a portfolio management model 
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for pharmaceutical companies manufacturing generic or 
similar medicines, a reference model to be used during the 
case studies was required. The Portfolio Management mo-
del proposed by Cooper, Edgett and Kleinschmidt (1998) 
was chosen to be used as the basis for theoretical reference. 
The reasons that justify this choice are as follows: i) it is 
specific for new product portfolio management; ii) the 
model presents an integration between the strategic and 
tactic levels of the company; iii) it is managerial in nature, 
i.e. it is not merely a sequence of steps; iv) the model is 
adaptable to the company’s criteria and strategies; v) the 
model stimulates the evolution of  Product Development 
Management (PDM) in the company. Successful portfolio 
management depends on the choice of criteria. The portfo-
lio management in the pharmaceutical industry should take 
into consideration, besides the standard criteria such as 
those presented by Oliveira and Rozenfeld (2007), Cooper, 
Edgett and Kleinschmidt (1997) and Bitman (2005), some 
specific criteria, namely, social relevance, expiration of 
patents, raw material availability and sanitary legislation.
Social Relevance
The social relevance of a product can be defined 
as the impact a given product has on public health. The 
pursuit of a financial return for new products is unques-
tionable. However, considering the importance of a 
pharmaceutical product to people’s quality of life and life 
expectation, it is essential to stimulate the development of 
new products that contribute to this end. 
The social relevance of new pharmaceutical pro-
ducts is evident in the development of i) new drugs for rare 
diseases that are not of great commercial interest because 
of the low demand for them; ii) new drugs for neglec-
ted diseases which are not of commercial interest since 
these diseases only afflict poor countries; iii) vaccines 
that reduce the incidence of diseases and, consequently, 
present decreasing financial returns; iv) medicines with 
low financial return that meet basic public health needs; 
v) phytotherapeutic medicines that can be low cost and 
meet basic public health needs, and also keep the popular 
culture active. Moreira (2008) describes each of these 
cases in her research. 
Monitoring of patents
It is widely known that the Brazilian pharmaceutical 
industry concentrates its R&D (Research & Development) 
activities on pharmaceutical-technical development and 
creates practically no new molecules. Pharmaceutical-
technical development consists basically of the develop-
ment of formulations for administration of drugs whose 
patents have expired and which lead to generic or similar 
medicines. 
The generic and similar medicine industry only 
grows because of the increased R&D of innovative medi-
cines. After expiration of the patents of these innovative 
medicines, all companies are allowed to manufacture the 
medicine. This situation offers a virtually free asset to the 
companies manufacturing generic and similar medicines, 
which are allowed to trade their medicines replacing the 
innovative products at very low prices, typically reduced 
by approximately 40% (ANVISA, 2002). The main pa-
tented products, whose current sales exceed one billion 
units worldwide and whose patents are set to expire within 
the next five years, are worth 80 billion dollars in terms 
of projected sales. This situation provides the companies 
manufacturing generic and similar medicines with growth 
opportunities (IFPMA, 2004). For this reason the moni-
toring of patents due to expire is essential to the portfolio 
management of the generic and similar medicine pharma-
ceutical industry.
Author
Cooper et al. 
(1998)
Archer and 
Ghasemzadeh 
(1999)
Kavadias 
(2001)
Bitman and 
Sharif (2007)
Correia (2005) Pereira (2002) Oliveira (2007) Costello (1983)
Focus of the 
model
New products Projects Projects New products
Software 
projects
New products 
and services
New dressing 
products
Projects
Sequence partial yes no yes Yes no yes yes
Flexibility Yes yes yes no Yes yes yes yes
Time scale No yes no partial partial no partial yes
Continuous Yes no yes yes Yes yes no no
Systemic Yes no yes yes Yes yes yes yes
Important 
characteristic
Interconnection 
between 
operational 
and strategic 
dimensions
Logical sequence 
of the steps 
facilitates practical 
application
Quantitative 
analysis
Created from 
analyses with 
Research and 
Development 
managers
Emphasizes 
the importance 
of Knowledge 
Management
Applied in 
a private 
research and 
development 
institute
Created to 
meet a clothing 
company’s 
needs
Use of the 
time scale and 
incorporation 
of all the 
hierarchical 
levels
FIGURE 1 - Portfolio Management models assessed and their characteristics.
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Sanitary legislation
Sanitary legislation has a great impact on pharma-
ceutical R&D. A recent study has reported an estimated 
cost of 802 million dollars to perform an innovative medi-
cine development process, from the selection of molecules 
to market launch. In the 1980s and 1990s, the estimated 
cost amounted to 230 and 500 million dollars, respectively 
(EFPIA, 2004). These costs have increased sharply becau-
se of the increased number of patients required for clinical 
trials and the increased number of clinical tests per order 
of new medicine (THE BOSTON, 1993). 
In the home pharmaceutical industry, the impact 
of the stricter sanitary legislation is notable. In Janua-
ry 1999, the enforcement of Generic Law (Law 9787) 
changed the structure of the pharmaceutical segment. 
It is unquestionable that this resulted in stricter control 
of the safety and quality of the medicines offered to 
the population, as well as in broader access to these 
products, in view of the competitiveness and reduced 
prices. This stricter control of the safety and quality of 
the medicines stems from the required bioequivalence 
and pharmaceutical equivalence tests. These tests are 
performed by laboratories qualified and/or certified by 
ANVISA, which compare the generic medicines to their 
respective patented reference medicines. In May 2003, 
new changes were made to the technical regulations re-
lated to medicine registration, such as the requirement of 
pharmaceutical equivalence and relative bioavailability 
tests for registration of similar medicines, as was already 
required for generic medicines (ANVISA, 2006). These 
changes have impacted the PDM in the Brazilian phar-
maceutical industry, because higher financial investments 
have been needed to defray the new tests.
The sanitary legislation is a criterion that should be 
taken into account in Portfolio Management, since the 
company needs to define which type of medicine shall 
be registered. Each type of medicine has its own specific 
legislation and requires different financial investments. 
Besides this, the marketing strategy of a similar medicine 
is different to that of a generic medicine. A similar medi-
cine has a trade name that needs to be made known to be 
traded, which is not applicable to the generic medicine.
Raw material availability
Raw material availability impacts the portfolio ma-
nagement of Brazilian pharmaceutical companies. Brazil 
is highly dependent on the import of pharmaceutical 
chemical substances, and active substance manufacturers 
are required to meet several regulatory requirements for 
ANVISA registration of the product. The sanitary legis-
lation for product registration requires evidence of the 
quality of the pharmaceutical chemical substance and 
supplier qualification. The results of the bioequivalence 
and bioavailability tests are also influenced by the phy-
sical characteristics of the raw materials. Consequently, 
the company needs to be sure it will be able to purchase 
the raw material in the necessary quantity and quality and 
at a compatible cost. The level of difficulty in purchasing 
the suitable raw material impacts the product launch time.
The portfolio management model proposed by 
Cooper, Edgett and Kleinschmidt (1998) and the specific 
criteria for the Brazilian pharmaceutical companies served 
as the theoretical reference for these case studies.
MATERIAL AND METHODS
Case studies are an empirical investigation that 
examine a contemporary phenomenon within its context, 
especially where the limits between the phenomenon and 
the context are not clearly defined. This method has been 
the preferred strategy in dealing with “how” and “why” 
research issues, when the researcher has little control over 
events and when the focus is on  contemporary phenomena 
occurring in some real life context (YIN, 2005).
In this paper, the method has been conducted ac-
cording to Figure 2. The figure shows that the initial step 
in designing the study consists of the development of the 
theory. The theory has been developed from the review of 
the literature, followed by the selection of cases and de-
velopment of protocol. The protocol presents the research 
problem, the theoretical basis and the data collection gui-
delines. The guidelines contain the selected cases, the form 
of contact with the companies, the preparation to visit the 
company, the interview questionnaire and the documents 
to be requested from the company. The case studies were 
performed individually. After the individual analysis of the 
cases, a crossed analysis of the cases was performed, in 
order to reach conclusions about replication and divergent 
results. The theory was revised based on this analysis, and 
a final conclusion was reached leading to a proposal of a 
managerial standard for portfolio management in Brazilian 
pharmaceutical companies. 
Given that the Brazilian pharmaceutical sphere 
encompasses two types of medicine companies – priva-
te pharmaceutical companies and official laboratories 
(government sponsored laboratories), it was decided to 
select at least one company of each type in order to repli-
cate the results. Case studies were performed involving 
three private companies (P1, P2 and P3) and one official 
laboratory (O1). The main data collection instrument was 
the semi-structured qualitative interview. As defined in 
the protocol, interviews with professionals related to the 
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product development process were scheduled. The other 
forms of data collection consisted of observations of the 
work environment, reference to documents made available 
Company Code P1 P2 P3 O1
Location Minas Gerais Minas Gerais Minas Gerais Southeast
Number of employees 320 210 480 425
Built-up area (m2) 12000 3860 6900 Not informed
Annual gross revenues (R$ 
millions)
35 25 > 20 Not informed
Number of traded products 83 68 50 43
GMP Certification yes Yes yes yes
Position of the interviewees and 
time in the company
Development Manager – 
5.5 years /
Industrial Director – 6 years
Development coordinator – 
3 years / Industrial Director – 
5 years
Development Manager – 
6 years
Development coordinator – 
3 years
Average development time 2 years 2 years 2 years 3 years
Number of launches in 2007 2 3 8 2
PDP informal None formal formal
Team responsible for development Development laboratory team Development laboratory team Multidisciplinary team Development laboratory team
Partnerships with research centers None Only for phytotherapeutic medicines None yes
Financial planning None None None None
Satisfaction with the results Low Medium Low Low
New product selection process
informal, performed by the commercial 
board of directors with focus on the cost 
analysis
informal, performed by the commercial 
board of directors with focus on the cost 
analysis
informal, performed by the management 
with focus on the cost analysis
informal, performed by the president and 
development manager
Development strategy informal Informal informal Non-structured
Number of products under 
development
100 62 24 33
FIGURE 3 – Characteristics of the companies studied. 
SOURCE: adapted from YIN (2005) 
FIGURE 2 – Research method used.
by the company and to information available on ANVISA’s 
electronic website. 
RESULTS AND DISCUSSION
The case study in this paper was not intended to 
validate a portfolio management model for Brazilian phar-
maceutical companies. The intention was to establish the 
important criteria for portfolio management in these compa-
nies, to understand how they have been used to select new 
product development projects and to develop a tool to help 
these companies better define their portfolios. The characte-
ristics of the assessed companies are presented in Figure 3.
The case studies confirmed that the Brazilian phar-
maceutical companies are dedicated to the development 
of formulations and not to creating novel drugs. Several 
official laboratories have research departments, but few 
studies focus on the development of new medicines. The 
purposes of portfolio management described by Cooper, 
Edgett and Kleinschmidt (1998) are suited to the Brazilian 
pharmaceutical industry. The official laboratories em-
phasized strategic alignment by means of the criterion of 
social relevance whereas value maximization was strongly 
present in the private laboratories.
The private companies have pursued  improved team 
working. The official laboratory assessed is beginning to 
set up multidisciplinary work teams. None of the assessed 
companies was found to have a multidisciplinary PDM 
team. The professionals of the product development sector 
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did not participate in the selection of the development pro-
jects. The official laboratory made the company’s business 
strategy clear. Only one private company expressed this 
concern. All the assessed companies showed an interest in 
following an Analyzer strategy, based on the concept by 
Griffin and Page (1996). The companies presented a PDP 
focused on the Product Development sector.
Regarding key criteria for portfolio management 
of Brazilian pharmaceutical companies, the classification 
presented in Figure 4 was verified for each company.
None of the companies demonstrated use of patent 
monitoring data for selection of new product projects. 
All the products launched by the assessed companies had 
patents that expired more than two years previous. For the 
private companies, financial return was the main criterion 
for selection of new product development projects, while 
the main criterion for the official laboratories was social 
relevance. 
The case studies have demonstrated that compliance 
with sanitary legislation did not interfere with the selection 
of projects, since the private companies already had the 
necessary infrastructure to meet sanitary requirements. 
The official laboratory assessed was being reformed to 
modernize its infrastructure. Product launch time was cri-
tical for the private companies. The criterion “raw material 
availability” was found to be the most important factor in 
the selection of new product projects for the private com-
panies. Technical success was a criterion evaluated after 
selection of the project and was used to help prioritize the 
projects. However, projects cannot be aborted based on 
this criterion. The assessed companies held product deve-
lopment follow-up meetings, but there was no discussion 
about the selected and prioritized projects, as indicated in 
the results of the case study. 
Several key criteria have been identified for the 
selection of new product projects in the assessed compa-
nies. However, the absence of structured application of the 
criteria was clear. The selection of new product projects 
was made based on the tacit knowledge of the company 
owner. It is noteworthy that the assessed companies are 
currently implementing a product development process.
The case studies have fulfilled the purpose of ex-
ploring the theme of new product portfolio management 
in Brazilian pharmaceutical companies. The results have 
provided input for the development of a managerial stan-
dard for new product portfolio management in Brazilian 
pharmaceutical companies. 
Proposal of a managerial standard for new 
product portfolio management in brazilian 
pharmaceutical companies
As discussed in the introduction, the portfolio ma-
nagement model proposed by Cooper, Edgett and Kleins-
chmidt (1998) presents some characteristics (for example, 
practicality and simplicity) that make it more suited to the 
application of new product portfolio management for com-
panies that do not yet formally use this type of management. 
The case study results have been incorporated into the mo-
del to produce a proposal of a managerial standard for por-
tfolio management in Brazilian pharmaceutical companies. 
The cases have shown that the Brazilian pharma-
ceutical companies assessed had no structured portfolio 
management. The projects were selected by the company’s 
Criterion O1 P1 P2 P3
Monitoring of patents
Does not interfere 
with portfolio 
management
Not performed
Monitors patents, 
but result does 
not interfere 
with portfolio 
management
Not performed
Social relevance Necessary Not applicable
Financial return Necessary Necessary Necessary Necessary
Sanitary legislation
Does not interfere 
with portfolio 
management
Does not interfere 
with portfolio 
management
Does not interfere 
with portfolio 
management
Does not interfere 
with portfolio 
management
Raw material availability
Does not interfere 
with portfolio 
management
Necessary Necessary Necessary
Technical success Desirable Desirable Desirable Necessary
FIGURE 4 – Classification of key criteria in the assessed companies.
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top management with little influence from other sectors. 
Another characteristic was the number of new product pro-
jects developed simultaneously.  The companies often had 
no specific priority, but a group of priorities from which 
any project carried out must first meet the corporate goals. 
Another important aspect is the lack of a clear definition of 
the strategic purposes for development of new products. 
These main aspects have been taken into consideration in 
the managerial standard developed. 
A managerial standard here is defined as a standar-
dized procedure for implementation of a process. This 
paper proposes a simple structure model for implemen-
tation of new product portfolio management in Brazilian 
companies. This proposal can be regarded as the first level 
of evolution of the portfolio management in companies 
adopting a managerial standard. Following the implemen-
tation of the proposed model, improvement in portfolio 
management and, consequently, in Product Development 
Management, should take place naturally. 
The managerial standard for application of new 
product portfolio management in Brazilian pharmaceutical 
companies is centered on four basic principles:
a) Formation of the PDM team,
b) Definition of product development strategy,
c) PDP management,
d) Revision of the portfolio.
The principles depicted in Figure 5 were structured 
to illustrate the interaction among them. The application of 
each principle is described below. The purposes of portfo-
lio management in the Brazilian pharmaceutical industry 
are the same as those for other companies, as defined by 
Cooper, Edgett and Kleinschmidt (1998): strategic alig-
nment, maximized value, and balancing. To facilitate the 
operation of the portfolio management process, the use of 
a Portfolio Management Work Spreadsheet is suggested 
for recording and displaying the evaluations.
FIGURE 5 – Proposal of managerial standard for new product portfolio management in Brazilian pharmaceutical companies.
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a) Forming product development management team
The first step toward application of portfolio mana-
gement is to build a team. The company’s top management 
should set up a multidisciplinary team. The team should 
have representatives that can perform the responsibilities 
described in Figure 6. The bundling of several responsibili-
ties can be an alternative when the company is medium si-
zed – for example, the top management can be responsible 
for the financial activities while the project management 
can oversee the product development sector. 
It is recommended that the team comprises 3 to 8 
members each dedicating at least 10% of their working 
hours to portfolio management. This team is not respon-
sible for the execution of the project itself. To make the 
product, the project management should appoint a team 
consisting of technical professionals fully dedicated to the 
execution of the project. The team should be qualified to 
carry out their functions. 
b) Definition of product development strategy
The definition of the product development strategy 
is the framework that shall guide the other principles in 
portfolio management. As the Brazilian pharmaceutical 
companies assessed did not clearly present the product 
development strategy, it is suggested that the strategic 
new product development objectives should be directly 
deployed from the business strategy. Using this approach, 
the company’s top management can present the Product 
Development Management team with what is expected 
from the product launches in a direct and summarized 
FIGURE 6 – Responsibility matrix of PDM team representatives.
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manner. The current level of maturity of the companies 
assessed hindered the deployment of the new product 
development strategy from the business strategy. 
The official laboratories must take into considera-
tion the strategic objectives related to Social Relevance 
which can entail the development of new drugs for rare 
or neglected diseases, vaccines, medicines for primary 
pharmaceutical care, or phytotherapeutic substances. 
The definition of strategic objectives is essential 
to structure portfolio management and can be performed 
by the Brazilian pharmaceutical industry. The top ma-
nagement should present the new product development 
objectives in a direct and summarized manner. This faci-
litates the communication of the objectives and confers 
flexibility to the top management, which can prioritize 
some objectives over time and revise them annually. The 
company’s new product development strategy should be 
defined upon the evolution of the Product Development 
Management. It is suggested that the strategy typology 
classification proposed by Griffin and Page (1996) be 
followed. Based on the strategy selected by the company, 
balancing the projects by project typology will contribute 
toward attaining the portfolio management objectives. For 
example, if a company defines that its new product deve-
lopment strategy is to be a pioneer among the Brazilian 
pharmaceutical companies and be an analyzer among the 
multinational pharmaceutical companies, then most of its 
projects should be related to new generic medicines in the 
home market. When the projects are classified by type, the 
project typology should be added to the work spreadsheet, 
in order to associate this with the strategic objective and 
provide data for evaluation of project balance. 
c) PDP Management
PDP Management is the operational principle of 
portfolio management. During the product development 
process, the new product project shall be submitted to 
an evaluation process that determines its feasibility and 
priority. 
This portfolio management application procedure 
consists of a simple, practical structure for evaluation of 
new product projects by the PDM team. The difference 
between the process performed by the private industry 
and that performed by the official laboratory is the idea 
of generating source. The PDP Management steps are 
described below.
i) Stage: generation of ideas
The generation of ideas is the beginning of the PDP 
process and should be performed considering the internal 
and external environment. The sources of ideas that yield 
greatest benefits with least investment of effort should be 
considered. The main idea generating sources for a private 
company consists of the monitoring of patents, market 
research with distributors, feedback from clients, and 
evaluation of internal strengths. The official laboratories 
should substitute the supplier surveys and feedback from 
clients, with the lists of medicines provided by the public 
health programs, together with data on distribution of 
exceptional medicines and meetings held by the Ministry 
of Health and Health Secretariats. 
The monitoring of patents can be performed by 
specific databases or by service providers. The companies 
should search for information on the patents set to expire 
within the next 10 years. The official laboratories can 
extract possible candidate drugs for future use in public 
health programs from patents to be expired and discuss 
them in meetings with the Ministry of Health.
Market research with distributors, who are the pri-
mary clients of the private companies, should provide data 
on the sales of a given product and prospective markets. 
The secondary clients, who are the drugstore owners, 
should provide ideas about improvements in existing pro-
ducts, either in the packaging or regarding the associations 
of products. This market research should be performed by 
the company’s sales team during routine visits. The use 
of a questionnaire is suggested for the sales professional 
to search for important information and to later generate 
ideas from all the clients visited. A survey by Client Sup-
port can also produce ideas for improvement.
The official laboratories should search for data on 
the distribution of health program medicines and excep-
tional medicines. Periodical meetings can be held between 
professionals of the public health sector and government 
members. The lists of health program medicines can be 
discussed in these meetings. The official laboratories 
should participate in these meetings by seeking ideas on 
new products for use by the public health programs. 
Research into internal strengths should be performed 
in order to seek ideas that can result in quick gains. The 
existing technical knowledge, the underutilization of equi-
pment, the product return rates and other issues should be 
investigated. This research can, for example, indicate an 
innovative line of products from the technical knowledge 
of a certain professional of the company. Research into 
internal strengths should be performed by professionals 
with an enterprising vision. It is suggested that the top 
management perform this research half-yearly. 
ii) Stage: Survey of strategic impact
The survey of the strategic impact on the Brazilian 
pharmaceutical industry should be performed by the top 
management and the PDM team. Each idea proposed 
should be discussed taking into account its impact on the 
R. A. Moreira, L. C. Cheng62
company’s strategic objectives. In the official laboratories, 
the Social Relevance criterion must be analyzed in this 
step, since the mission of these companies is to contribute 
to the growth of the Public Health System.  
Each idea should be assigned a score representing 
the impact on a given strategic objective where each idea 
can also be classified as high, medium or low impact for 
the strategic objective. This step consists of a survey, and 
involves no decision making. The impact is evaluated at 
each consecutive step, which in practice can be done at the 
same meeting as that of the survey of the strategic impact.
iii) Gate: Screening 1 – Evaluation of strategic 
impact
The evaluation of the strategic impact on the Brazi-
lian pharmaceutical industry should be performed by the 
company’s top management in this implementation of the 
portfolio management model. The evaluation by the top 
management shall be recorded and communicated to the 
portfolio management team in order to build a knowledge 
base in the company.  The evaluation must next be per-
formed by the portfolio management team, where the top 
management shall only be responsible for the Portfolio 
Revision. 
The evaluation of the strategic impact shall classify 
each project as high, medium or low impact or add/mul-
tiply the score of the previous step. In this step projects 
may be aborted should their idea not be aligned with the 
strategic objectives. 
iv) Stage: Analysis of financial return
Financial return must be analyzed at the outset of the 
project classification process. There are several methods to 
calculate the financial return of projects. The application of 
simple methods, which can evolve with time, is suggested 
in the implementation of the portfolio management model, 
according to the example outlined below.
At this initial stage, companies can analyze the 
financial return based on the calculation of the reference 
medicine formulation cost and its maximum price. The 
maximum price of the new product takes into considera-
tion the prices of the competing medicines. The drugstore’s 
margin, distributor’s margin and manufacturer’s margin of 
profit are deducted from the maximum price, thus reaching 
a maximum cost for comparison against the manufacturing 
cost. Since the financial analysis is performed at the outset 
of the process, the team should use the reference medicine 
for calculation of the manufacturing cost. To survey es-
timated demand, the team should conduct research with 
distributors in order to ascertain the sales of the competing 
medicines. From these data it is possible to evaluate the 
financial feasibility of the product. Should there be no 
reference medicine, the definition of a theoretical formu-
la for the product will be required, where this formula 
should be proposed by the pharmaceutical development 
professionals. 
The official laboratories should be attentive to the 
financial return. As they are public institutions they run the 
risk of disregarding financial calculations essential to the 
survival of the company. Instead of the abovementioned 
research with distributors used by the private companies, 
the official company should draw on data regarding distri-
bution of the product by the public health services. 
The highest investment in the development of a si-
milar/generic pharmaceutical product is usually the costs 
of the relative bioavailability/bioequivalence test. During 
the analysis of the financial return, it should be evaluated 
whether there will be additional investments that impact 
the product development cost. 
v) Gate: Screening 2 – Evaluation of financial return
To evaluate the financial return, the top management 
needs to define the minimum demand which would make 
the product an interesting commercial proposition for the 
company. The manufacturing cost calculated should be 
lower than the target cost. The case studies have demons-
trated that at present, the top management lacks informa-
tion on financial return values. Therefore, the company 
can initially choose to delegate the responsibility for this 
step to the top management, which should classify the 
financial return as high, medium or low. This screening 
enables aborting of projects considered non-profitable in 
the evaluation of the financial return.
vi) Stage: Analysis of desirable criteria
This step consists of the analysis of criteria which are 
important to the company, such as technical success and 
availability of raw material. The results of the case studies 
show that these two criteria were essential to the selection 
of projects in the assessed companies. The participation of 
the PDM team is intense in this step. The analysis of these 
criteria will contribute to the selection of the projects and, 
consequently, to the progress of the PDP. 
The technical success is analyzed by the technical 
professionals, including the pharmaceutical development, 
production, quality control, quality assurance and regu-
latory affairs sectors. The use of a checklist to guide this 
analysis is suggested. An example checklist is presented 
in Figure 7. Prior to its application, the company should 
adapt the list to suit its specificities, taking into account the 
items assessed, the weights assigned and the scoring scale.
The availability of raw material should be taken into 
consideration since it represents a factor determining total 
development time. The evaluation of this item requires the 
full participation of the purchasing sector and a techni-
cal representative to evaluate aspects related to supplier 
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qualification. The decision tree presented in Figure 8 is a 
tool to evaluate the availability of raw material. The differ-
ence between manufacturer and distributor is noteworthy. 
The manufacturer is a company that manufactures raw 
material. The raw material can be sold directly, either to 
a pharmaceutical company or to an intermediate agent, 
which is the distributor.
vii) Gate: Prioritization
This step is the consolidation of the PDP Manage-
ment principle. As the pharmaceutical companies deal with 
several development projects simultaneously, prioritiza-
tion by groups is suggested. The Priority 1 group should 
include the projects considered essential to the company. 
There should also be prioritization within each group to 
organize the sequence of work. 
Prioritization should take into consideration the ba-
lancing of projects.  Some criteria which are important to 
balance the projects, such as impacted strategic objective, 
product family or type of project, should be used.
d) Portfolio revision
The Portfolio Revision entails a periodical evalua-
Classification Item assessed
Yes
(5 pts)
No, 
requiring 
little effort
(3 pts)
No, 
requiring 
a lot of 
effort
(1 pt)
Pharmacological-
technical and 
quality control 
aspects 
Weight: 2
Are there other products with the same 
pharmaceutical form?
Is the active substance analysis methodology 
pharmacopoeic? 
Are there other products that use the same 
excipients?
Are there other products that use the same 
packaging materials?
Do the relative bioavailability/bioequivalence 
tests follow the standard (that is, there are no 
features that hinder the process)?
Does the validation of the process follow the 
standard (that is, there are no features that 
hinder the process)?
Infrastructure 
aspects
Weight: 2
Is there infrastructure (equipment, area, utilities, 
etc.) for the industrial production?
Is there infrastructure (equipment, area, utilities, 
etc.) for the development?
Is there infrastructure (equipment, area, utilities, 
etc.) for the stability assessments?
Is there infrastructure (equipment, area, utilities, 
etc.) for the industrial production?
Is there infrastructure (equipment, area, utilities, 
etc.) for the quality control?
Does the current productive capacity 
accommodate the new product?
Regulatory 
aspects
Weight: 1
Does the regulatory register dossier follow the 
standard format (that is, there are no features 
that hinder the process)?
Is the new product in conformity with the GMP?
Is the new product in conformity with the safety 
standards?
FIGURE 7 – Checklist for evaluation of technical success.
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tion by the Top Management of the projects included in 
each Priority Group. A quarterly revision is suggested in 
the first two years of application of the portfolio mana-
gement. From the third year on, a half-yearly revision is 
suggested. The portfolio revision should be planned by the 
Product Development management.
The Portfolio Revision process consists of answe-
ring the following questions:
1st ) Is there any project that needs to be carried out now?
2nd ) Do the prioritized projects meet the company’s stra-
tegic objectives?
3rd ) Are the prioritized projects balanced?
4th ) Is it necessary to adjust the PDP?
 In discussing the first question, the portfolio revi-
sion team can request a certain project to be prioritized 
due to  recent information acquired on the same product 
being launched by a competitor or because the sale of 
another product depends on this new product. The second 
question should be discussed to confirm that the PDM 
team understands the company’s strategy and is able 
to translate it into new products. The project balancing 
discussed in the third question may take several criteria 
into consideration. It is important that the criteria used for 
balancing during the Portfolio Revision are the same as 
those used by the PDM team. During the Portfolio Revi-
sion, new criteria important for portfolio management can 
be identified. These criteria shall be immediately informed 
to the portfolio management team for adjustment of the 
PDP, thus answering the fourth question. The Portfolio 
Revision should use tools to facilitate the analysis by the 
top management, such as bubble diagrams. As explained 
by Cooper, Edgett and Kleinschmidt (1998), the portfolio 
revision can become a mere formalization of the portfolio 
management, and no adjustments will be required after the 
revision. This may occur in the Brazilian pharmaceutical 
companies assessed as the knowledge base of the PDM 
FIGURE 8 – Decision tree for evaluation of raw material availability.
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team enlarges and the portfolio management becomes truly 
implemented in the company. 
CONCLUSION
This research has produced a proposal of a mana-
gerial standard for new product portfolio management in 
Brazilian pharmaceutical companies, based on revision of 
the literature and results of case studies. An absence of re-
ferences on this theme for Brazilian companies was noted 
during the review of literature. Selection and prioritization 
papers using quantitative methods for innovative medici-
nes are more frequent. Since this scenario is unlikely in 
the Brazilian pharmaceutical industry for the foreseeable 
future,  a theoretical portfolio management model was 
elected to serve as a conceptual basis for these case studies.
The proposal of a standard for application of new 
product portfolio management in Brazilian pharmaceutical 
companies is managerial, systemic and flexible: i) it is ma-
nagerial because it possesses the tactical/operational and 
strategic dimensions in a manner allowing its application 
to lead to continuous evolution of Product Development 
Management; ii) it is systemic because it interconnects the 
components of Product Development Management and 
requires a multidisciplinary team; iii) it is flexible because 
it can be adapted to accommodate different companies 
and stages of evolution and allows the use of different 
methods and tools. 
Although the managerial standard presents a structu-
re for practical application, it is still theoretical since it has 
not yet been submitted to evaluation or implementation in 
the companies. It is important to note that the managerial 
standard embraces characteristics of the similar and gene-
ric medicine industry that deal basically with incremental 
research. Innovative research into new medicines is not 
covered by this managerial standard.
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